Compare Stocks: DRUG, COLL, ARDX, and HELP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.20 +5.4%	$3.40	$2.95 ▼ $8.40	$796.16M	0.79	4.28 million shs	2.75 million shs
COLL Collegium Pharmaceutical	$23.86 +0.5%	$23.16	$21.43 ▼ $50.79	$776.88M	0.75	575,318 shs	119,183 shs
DRUG Bright Minds Biosciences	$19.50 -9.5%	$57.05	$18.90 ▼ $123.75	$189.71M	-5.11	212,791 shs	158,096 shs
HELP Cybin	$8.76 -3.0%	$11.81	$3.76 ▼ $15.15	$699.06M	0.64	1.28 million shs	271,007 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	+1.00%	-9.28%	-38.29%	-48.82%
COLL Collegium Pharmaceutical	+0.21%	+3.17%	+7.77%	-33.59%	-34.27%
DRUG Bright Minds Biosciences	-17.75%	-60.11%	-57.49%	-73.06%	-58.12%
HELP Cybin	+2.61%	-14.16%	-22.82%	-14.25%	+902,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.20 +5.4%	$3.40	$2.95 ▼ $8.40	$796.16M	0.79	4.28 million shs	2.75 million shs
COLL Collegium Pharmaceutical	$23.86 +0.5%	$23.16	$21.43 ▼ $50.79	$776.88M	0.75	575,318 shs	119,183 shs
DRUG Bright Minds Biosciences	$19.50 -9.5%	$57.05	$18.90 ▼ $123.75	$189.71M	-5.11	212,791 shs	158,096 shs
HELP Cybin	$8.76 -3.0%	$11.81	$3.76 ▼ $15.15	$699.06M	0.64	1.28 million shs	271,007 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	+1.00%	-9.28%	-38.29%	-48.82%
COLL Collegium Pharmaceutical	+0.21%	+3.17%	+7.77%	-33.59%	-34.27%
DRUG Bright Minds Biosciences	-17.75%	-60.11%	-57.49%	-73.06%	-58.12%
HELP Cybin	+2.61%	-14.16%	-22.82%	-14.25%	+902,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.83	Moderate Buy	$13.90	335.05% Upside
COLL Collegium Pharmaceutical	2.78	Moderate Buy	$48.71	104.17% Upside
DRUG Bright Minds Biosciences	2.92	Moderate Buy	$126.29	547.79% Upside
HELP Cybin	3.00	Buy	$47.33	440.40% Upside

Current Analyst Ratings Breakdown

Latest DRUG, COLL, ARDX, and HELP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/3/2026	DRUG Bright Minds Biosciences	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$126.00 ➝ $107.00
11/2/2026	DRUG Bright Minds Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$147.00 ➝ $37.00
11/2/2026	DRUG Bright Minds Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/22/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$16.00 ➝ $22.00
10/16/2026	ARDX Ardelyx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/15/2026	COLL Collegium Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Strong-Buy
10/15/2026	DRUG Bright Minds Biosciences	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$150.00
10/6/2026	COLL Collegium Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/28/2026	DRUG Bright Minds Biosciences	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/25/2026	ARDX Ardelyx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/23/2026	COLL Collegium Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$50.00

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	1.95	N/A	N/A	$0.69 per share	4.63
COLL Collegium Pharmaceutical	$780.57M	1.00	$15.29 per share	1.56	$9.54 per share	2.50
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	13.31	N/A	-12.35%	-36.00%	-10.77%	N/A
COLL Collegium Pharmaceutical	$62.87M	$1.24	19.24	4.05	0.74	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	12/22/2026 (Estimated)
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A

Latest DRUG, COLL, ARDX, and HELP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	COLL Collegium Pharmaceutical	$1.86	N/A	N/A	N/A	$216.03 million	N/A
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
COLL Collegium Pharmaceutical	3.32	1.03	0.84
DRUG Bright Minds Biosciences	N/A	122.00	122.00
HELP Cybin	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
COLL Collegium Pharmaceutical	N/A
DRUG Bright Minds Biosciences	40.52%
HELP Cybin	17.94%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
COLL Collegium Pharmaceutical	1.85%
DRUG Bright Minds Biosciences	42.66%
HELP Cybin	15.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
COLL Collegium Pharmaceutical	423	32.56 million	31.95 million	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Optionable
HELP Cybin	100	79.81 million	67.84 million	Optionable

DRUG, COLL, ARDX, and HELP Headlines

Recent News About These Companies

Cybin Inc. (NASDAQ:HELP) Stock Has Consensus Target Price of $47.33 According to Analysts

November 4 at 6:13 AM | marketbeat.com

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

November 3 at 7:30 AM | globenewswire.com

Cybin (NASDAQ:HELP) Stock Price Down 6.6% - Here's What Happened

November 2 at 12:20 PM | marketbeat.com

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development

October 27, 2026 | globenewswire.com

Cybin (NASDAQ:HELP) Raised to Sell at Wall Street Zen

October 25, 2026 | marketbeat.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Cybin (NASDAQ:HELP) Stock

October 24, 2026 | americanbankingnews.com

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health - Slideshow

October 23, 2026 | seekingalpha.com

Cybin (NASDAQ:HELP) Stock Price Target Raised at Wells Fargo & Company

October 22, 2026 | marketbeat.com

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

October 21, 2026 | seekingalpha.com

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

October 21, 2026 | globenewswire.com

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

October 21, 2026 | marketbeat.com

Cybin Sees Unusually High Options Volume (NASDAQ:HELP)

October 21, 2026 | marketbeat.com

Cybin Inc. (HELP) upgraded to buy: What does it mean for the stock?

October 20, 2026 | msn.com

Cybin (NASDAQ:HELP) Upgraded at Wall Street Zen

October 17, 2026 | marketbeat.com

Cybin (NASDAQ:HELP) Shares Down 4.5% - Here's What Happened

October 16, 2026 | marketbeat.com

WealthPlan Investment Management LLC Makes New $1.27 Million Investment in Cybin Inc. $HELP

October 16, 2026 | marketbeat.com

Cybin (NASDAQ:HELP) Stock Jumps 6.5% - Here's Why

October 15, 2026 | marketbeat.com

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

October 15, 2026 | globenewswire.com

Cybin (NASDAQ:HELP) Stock Falls 1.1% - Here's Why

October 14, 2026 | marketbeat.com

Cybin (NASDAQ:HELP) Stock Price Down 4.8% - Should You Sell?

October 13, 2026 | marketbeat.com

Cybin (NASDAQ:HELP) Stock Falls 5.6% - Should You Sell?

October 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, COLL, ARDX, and HELP Company Descriptions

Ardelyx NASDAQ:ARDX

$3.20 +0.17 (+5.45%)

As of 11:19 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$23.86 +0.13 (+0.55%)

As of 11:18 AM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$19.50 -2.06 (-9.54%)

As of 11:19 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Cybin NASDAQ:HELP

$8.76 -0.27 (-3.00%)

As of 11:18 AM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, COLL, ARDX, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, COLL, ARDX, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, COLL, ARDX, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, COLL, ARDX, and HELP Company Descriptions

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Bright Minds Biosciences NASDAQ:DRUG

Cybin NASDAQ:HELP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, COLL, ARDX, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, COLL, ARDX, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, COLL, ARDX, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, COLL, ARDX, and HELP Company Descriptions

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Bright Minds Biosciences NASDAQ:DRUG

Cybin NASDAQ:HELP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools